Poxel Announces Submission of Imeglimin Japanese New Drug Application for the Treatment of Type 2 Diabetes by Sumitomo Dainippon Pharma Jul 30, 2020
Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2020 Jul 21, 2020
Poxel Announces Results from June 24, 2020 Ordinary Annual and Extraordinary General Meeting Jun 25, 2020
Poxel Announces Positive Pharmacokinetic (PK) / Pharmacodynamic (PD) Study Results for PXL770, a Direct AMPK Activator for the Treatment of NASH Jun 24, 2020
Poxel Announces Program Update and Preclinical Results on PXL770 for NASH Combinations and Other Metabolic Diseases May 25, 2020
Poxel Announces Publication of Imeglimin Clinical Study Results in Clinical Pharmacokinetics Apr 20, 2020
